
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics is a strong and growing company with a unique product in the current mental health market. With its NeuroStar Advance Therapy System, the company offers a non-invasive alternative for treating depression and has a well-developed commercial model to reach a larger customer base. The company is also well-positioned for future growth with its collaboration with Compass Pathways for psilocybin therapy and its recent integration with AdvancedMD for improved revenue cycle management. The company has shown positive financial results with increased revenue and gross margin and a move towards sustained profitability.
Bears say
Neuronetics is facing numerous unknowns in the emerging field of interventional psychiatry, specifically with the anticipated commercial launch of COMP360, a psilocybin therapy. While the company has some competitive advantages in this space, such as an existing collaboration with COMPASS, operational infrastructure, and available capacity, it is still unclear how the opportunity for this type of therapy will play out in terms of FDA approval, reimbursement, and utilization among patients and physicians. Additionally, the company's traditional NeuroStar treatment model is facing challenges and transition as they incorporate a new go-to-market strategy.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares